Busca avançada
Ano de início
Entree


Inhibitor induced conformational changes in SARS-COV-2 papain-like protease

Texto completo
Autor(es):
Ferreira, Glaucio Monteiro ; Pillaiyar, Thanigaimalai ; Hirata, Mario Hiroyuki ; Poso, Antti ; Kronenberger, Thales
Número total de Autores: 5
Tipo de documento: Artigo Científico
Fonte: SCIENTIFIC REPORTS; v. 12, n. 1, p. 13-pg., 2022-07-08.
Resumo

SARS-CoV-2's papain-like protease (PLpro) interaction with ligands has recently been explored with a myriad of crystal structures. We used molecular dynamics (MD) simulations to study different PLpro-ligand complexes, their ligand-induced conformational changes, and interactions. We focused on inhibitors reported with known IC50 against PLpro, namely GRL-0617, XR8-89, PLP_Snyder530, and Sander's recently published compound 7 (CPD7), and compared these trajectories against the apostructure (Apo), with a total of around 60 mu s worth simulation data. We aimed to study the conformational changes using molecular dynamics simulations for the inhibitors in the PLpro. PCA analyses and the MSM models revealed distinct conformations of PLpro in the absence/presence of ligands and proposed that BL2-loop contributes to the accessibility of these inhibitors. Further, bulkier substituents closer to Tyr268 and Gln269 could improve inhibition of SARS-CoV-2 PLpro by occupying the region between BL2-groove and BL2-loop, but we also expand on the relevance of exploring multiple PLpro sub-pockets to improve inhibition. (AU)

Processo FAPESP: 16/12899-6 - Caracterização genômica, epigenômica e farmacogenômica de portadores de hipercolesterolemia familial na população brasileira
Beneficiário:Mario Hiroyuki Hirata
Modalidade de apoio: Auxílio à Pesquisa - Temático
Processo FAPESP: 19/24112-9 - Desenvolvimento de novos inibidores da HMG-CoA redutase, integrando estudos genéticos e modelagem molecular de pacientes dislipidêmicos
Beneficiário:Glaucio Monteiro Ferreira
Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Pós-Doutorado
Processo FAPESP: 21/11205-9 - Desenvolvimento de novos fármacos baseados na estrutura de proteínas essenciais para síntese e metabolismo do colesterol, integrando estudos genéticos e modelagem molecular de pacientes dislipidêmicos
Beneficiário:Glaucio Monteiro Ferreira
Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado